Company Of The Day: Pfizer
What?
Pfizer (NYSE:PFE) plans to acquire Biohaven Pharmaceutical, a company that specializes in migraine treatments, in a deal valued at about $11.6 billion.
Why?
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
- Is Pfizer Stock Undervalued At $40?
Pfizer is flush with cash from its Covid-19 vaccine and is looking at acquisitions to bolster revenue as vaccine sales peak off, with some of its top-selling drugs also set to go off patent.
So What?
We think Pfizer stock is undervalued. We value PFE at $63 per share, about 25% ahead of the current market price.
See Our Complete Analysis For Pfizer
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
| Returns | May 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| PFE Return | 1% | -16% | 52% |
| S&P 500 Return | -5% | -17% | 76% |
| Trefis Multi-Strategy Portfolio | -9% | -25% | 196% |
[1] Month-to-date and year-to-date as of 5/12/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates